Security Snapshot

Autolus Therapeutics plc - American Depositary Shares, each representing one ordinary share, par value $0.000042 per share (AUTL) Institutional Ownership

CUSIP: 05280R100

13F Institutional Holders and Ownership History from Q2 2018 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

90

Shares (Excl. Options)

139,415,643

Price

$1.99

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / American Depositary Shares, each representing one ordinary share, par value $0.000042 per share
Symbol
AUTL on Nasdaq
Shares outstanding
265,957,447
Price per share
$1.38
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
139,415,643
Total reported value
$277,208,770
% of total 13F portfolios
0%
Share change
-2,062,927
Value change
-$1,766,174
Number of holders
90
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • AUTL - Autolus Therapeutics plc - American Depositary Shares, each representing one ordinary share, par value $0.000042 per share is tracked under CUSIP 05280R100.
  • 90 institutions reported positions in Q4 2025.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 90 to 8 between Q4 2025 and Q1 2026.
  • Reported value moved from $277,208,770 to $239,282.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 90 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 05280R100?
CUSIP 05280R100 identifies AUTL - Autolus Therapeutics plc - American Depositary Shares, each representing one ordinary share, par value $0.000042 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Autolus Therapeutics plc - American Depositary Shares, each representing one ordinary share, par value $0.000042 per share (AUTL) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
MAK Capital Fund LP 11% +12% $41,107,320 +$4,271,434 30,005,343 +12% MAK Capital Fund LP 31 Dec 2025
Syncona Portfolio Ltd 11% $37,755,579 28,821,053 Syncona Portfolio Limited 31 Mar 2025
ARMISTICE CAPITAL, LLC 6.6% +12% $25,025,000 +$2,717,000 17,500,000 +12% Armistice Capital, LLC 31 Dec 2025
FMR LLC 3.8% $13,312,676 10,162,348 FMR LLC 31 Mar 2025
Deep Track Capital, LP 0.97% $4,186,839 2,568,613 Deep Track Capital, LP 30 Sep 2025

As of 31 Dec 2025, 90 institutional investors reported holding 139,415,643 shares of Autolus Therapeutics plc - American Depositary Shares, each representing one ordinary share, par value $0.000042 per share (AUTL). This represents 52% of the company’s total 265,957,447 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Autolus Therapeutics plc - American Depositary Shares, each representing one ordinary share, par value $0.000042 per share (AUTL) together control 51% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
MAK CAPITAL ONE LLC 11% 30,005,343 +15% 8% $59,710,633
Blackstone Inc. 7.7% 20,485,611 0% 0.18% $40,766,366
ARMISTICE CAPITAL, LLC 6.6% 17,500,000 +12% 0.85% $34,825,000
Syncona Portfolio Ltd 6.3% 16,640,720 0% 96% $33,115,033
Tetragon Partners GP Ltd 3.6% 9,500,000 0% 4% $18,905,000
SCHRODER INVESTMENT MANAGEMENT GROUP 3.6% 9,489,345 +13% 0.01% $18,694,010
Frazier Life Sciences Management, L.P. 1.7% 4,623,324 0% 0.25% $9,200,415
BlackRock, Inc. 1.4% 3,685,825 +6.1% 0% $7,334,792
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.3% 3,361,156 0.01% $6,689,000
Laurion Capital Management LP 1.2% 3,316,626 0% 0.45% $6,600,086
RENAISSANCE TECHNOLOGIES LLC 1.2% 3,105,404 -36% 0.01% $6,179,754
BANK OF AMERICA CORP /DE/ 0.74% 1,960,766 -3.4% 0% $3,901,924
ACADIAN ASSET MANAGEMENT LLC 0.68% 1,804,117 -2.7% 0.01% $3,580,000
MORGAN STANLEY 0.53% 1,397,251 +15% 0% $2,780,530
Atle Fund Management AB 0.44% 1,169,634 0% 0.74% $2,327,571
CITADEL ADVISORS LLC 0.44% 1,159,791 -81% 0% $2,307,984
Cetera Investment Advisers 0.41% 1,099,750 +37% 0% $2,188,503
JPMORGAN CHASE & CO 0.37% 979,275 +8.4% 0% $1,948,757
UBS Group AG 0.33% 877,100 +114% 0% $1,745,429
Alphabet Inc. 0.26% 698,262 0% 0.05% $1,389,541
JANE STREET GROUP, LLC 0.26% 681,000 -22% 0% $1,355,190
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.23% 598,987 +154% 0% $1,191,984
Hennion & Walsh Asset Management, Inc. 0.17% 453,828 +7.9% 0.03% $903,118
Privium Fund Management B.V. 0.12% 326,245 +5.6% 0.12% $649,228
Point72 Asset Management, L.P. 0.11% 305,359 0% $607,664

Institutional Holders of Autolus Therapeutics plc - American Depositary Shares, each representing one ordinary share, par value $0.000042 per share (AUTL) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 173,558 $239,282 -$320,429 $1.38 8
2025 Q4 139,415,643 $277,208,770 -$1,766,174 $1.99 90
2025 Q3 143,579,673 $233,669,297 -$67,552,879 $1.63 95
2025 Q2 165,944,662 $378,376,899 +$9,844,394 $2.28 93
2025 Q1 168,007,060 $260,819,521 -$3,531,773 $1.55 93
2024 Q4 168,335,372 $395,090,875 -$37,054,930 $2.35 107
2024 Q3 178,602,235 $648,320,594 +$2,536,180 $3.63 97
2024 Q2 178,106,548 $619,765,055 -$54,511,638 $3.48 106
2024 Q1 175,580,707 $1,120,176,501 +$380,385,653 $6.38 114
2023 Q4 115,868,017 $746,230,557 +$30,259,044 $6.44 97
2023 Q3 110,707,409 $257,962,960 +$2,926,164 $2.33 67
2023 Q2 109,330,876 $260,181,467 +$12,434,850 $2.38 67
2023 Q1 105,962,470 $194,950,415 -$3,026,243 $1.84 64
2022 Q4 107,371,378 $203,976,112 +$109,842,474 $1.90 69
2022 Q3 49,366,337 $105,661,961 -$3,352,319 $2.14 62
2022 Q2 50,829,136 $143,849,865 -$7,115,566 $2.83 57
2022 Q1 45,661,103 $190,513,250 -$17,791,387 $4.17 60
2021 Q4 52,463,220 $272,271,730 +$101,855,863 $5.19 69
2021 Q3 25,076,258 $164,226,984 -$2,136,433 $6.55 55
2021 Q2 25,378,541 $169,575,110 +$23,313,452 $6.64 64
2021 Q1 22,400,702 $128,321,739 +$53,655,759 $5.73 58
2020 Q4 12,635,638 $112,960,120 +$962,285 $8.94 46
2020 Q3 12,386,365 $143,379,095 -$24,849,875 $11.64 44
2020 Q2 14,328,662 $229,696,396 -$16,435,312 $16.03 48
2020 Q1 15,977,491 $96,357,056 +$6,942,585 $5.99 50
2019 Q4 13,423,917 $177,195,289 +$748,992 $13.20 54
2019 Q3 13,444,843 $166,969,346 -$100,503,433 $12.42 42
2019 Q2 21,383,578 $344,232,698 +$52,450,982 $16.10 45
2019 Q1 18,088,058 $569,233,000 +$34,027,507 $31.47 32
2018 Q4 16,988,795 $557,884,000 -$24,061,507 $32.84 36
2018 Q3 17,853,077 $546,310,000 +$275,258,001 $30.66 39
2018 Q2 9,009,943 $241,253,000 +$237,222,000 $26.79 49